Emergent BioSolutions launches biothrax.com

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced May 8, 2009, the launch of www.biothrax.com, a website that provides information about BioThrax, the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection.

The site contains information including published data and updates to prescribing information. In December 2008, the FDA approved the five-dose schedule and intramuscular route of administration for BioThrax.

“Information about recent product enhancements such as the five-dose schedule and intramuscular route of administration is made readily available on BioThrax.com,” said James Jackson, chief scientific officer of Emergent BioSolutions.

“Emergent has developed this website to provide information about the threat of anthrax and to help individuals make informed decisions.”

BioThrax.com is designed to be a central resource for government entities, health professionals and vaccine recipients, including military personnel, emergency responders and other people at high risk of exposure to anthrax. The site also provides facts on anthrax disease and the use of anthrax as a potential weapon of bioterrorism.

Since 1998, the U.S. government has procured nearly 33.5 million doses of BioThrax. During that time period, more than 8.4 million doses have been administered to more than 2.1 million military personnel.